

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
<b>Laszlo Matthew T</b>			<b>10/8/2014</b>		<b>CLOROX CO /DE/ [CLX]</b>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<b>1221 BROADWAY</b>			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>SVP - Chief Customer Officer /</b>				
(Street)			5. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)		
<b>OAKLAND, CA 94612-1888</b>					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City)	(State)	(Zip)					

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<b>Common Stock</b>	<b>1312.0000</b>	<b>D</b>	

### Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<b>Stock Option (Right to Buy)</b>	<b>9/14/2011</b> <a href="#">(1)</a>	<b>9/14/2020</b>	<b>Common Stock</b>	<b>593.0000</b>	<b>\$66.4800</b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>9/13/2012</b> <a href="#">(1)</a>	<b>9/13/2021</b>	<b>Common Stock</b>	<b>1190.0000</b>	<b>\$68.1500</b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>9/11/2013</b> <a href="#">(1)</a>	<b>9/11/2022</b>	<b>Common Stock</b>	<b>3960.0000</b>	<b>\$72.1100</b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>9/17/2014</b> <a href="#">(1)</a>	<b>9/17/2023</b>	<b>Common Stock</b>	<b>5640.0000</b>	<b>\$84.4500</b>	<b>D</b>	
<b>Stock Option (Right to Buy)</b>	<b>9/17/2015</b> <a href="#">(1)</a>	<b>9/17/2024</b>	<b>Common Stock</b>	<b>7450.0000</b>	<b>\$89.8200</b>	<b>D</b>	

#### Explanation of Responses:

(1) Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date.

#### Remarks:

poalasz.txt

#### Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Laszlo Matthew T 1221 BROADWAY OAKLAND, CA 94612-1888			SVP - Chief Customer Officer	

**Signatures**

**By Angela Hilt, Attorney-in-Fact for**

**10/10/2014**

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

October 8, 2014

Securities and Exchange Commission  
450 Fifth Street N.W.  
Washington, DC 20549

Ladies and Gentlemen:

This letter authorizes the following representatives of The Clorox Company, acting singly, to execute and file with you on my behalf future Forms 3, 4 and 5 respecting my holdings of equity securities of The Clorox Company:

Laura Stein, Senior Vice President - General Counsel Angela Hilt, Vice President - Corporate Secretary & Associate General Counsel Stephanie Tang, Corporate Counsel

Cheryl Brice, Assistant Secretary and Legal Specialist

Sincerely,

*/s/ Matthew Laszlo*  
*Name: Matthew Laszlo*  
*Title: SVP - Chief Customer Officer*